PET of EGFR antibody distribution in head and neck squamous cell carcinoma models.

ABSTRACT:

Unlabelled

Epidermal growth factor receptor (EGFR) is a well-characterized protooncogene that has been shown to promote tumor progression in solid cancers. Clinical results for EGFR targeting with specific monoclonal antibodies (mAbs) such as cetuximab and panitumumab are promising; however, most studies indicate that only a subgroup of patients receiving the mAbs benefit from the immunotherapy, independent of EGFR expression level. To understand the in vivo kinetics of antibody delivery and localization, we performed small-animal PET studies with (64)Cu-labeled panitumumab in xenografts derived from 3 cell lines of human head and neck squamous cell carcinoma (HNSCC).

Methods

Nude mice bearing HNSCC tumors with different levels of EGFR expression were imaged with small-anima

SUBMITTER: Niu G 

PROVIDER: S-EPMC6435376 | biostudies-literature | 2009 Jul

REPOSITORIES: biostudies-literature